JPH08503925A - 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物 - Google Patents
脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物Info
- Publication number
- JPH08503925A JPH08503925A JP6504330A JP50433094A JPH08503925A JP H08503925 A JPH08503925 A JP H08503925A JP 6504330 A JP6504330 A JP 6504330A JP 50433094 A JP50433094 A JP 50433094A JP H08503925 A JPH08503925 A JP H08503925A
- Authority
- JP
- Japan
- Prior art keywords
- cyclopentyloxy
- compound
- dichloropyrid
- formula
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/88—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/42—Y being a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
- C07C45/292—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups with chromium derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/60—Unsaturated compounds containing ether groups, groups, groups, or groups the non-carboxylic part of the ether being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/62—Unsaturated compounds containing ether groups, groups, groups, or groups containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
- C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/42—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ベンゼン誘導体が式I R1は低級アルキルであり; R2はアルキル、アルケニル、シクロアルキル、シクロアルケニル、シクロ チオアルキルまたはシクロチオアルケニルであり; R3はアリールまたはヘテロアリールであり; Z、Z1およびZ2は独立して酸素または硫黄であり; Z3は であり;そして Xはハロである、 である、TNFを抑制することによりモジュレートすることができる疾患状態を 治療するための医薬品を製造するための該ベンゼン誘導体、またはそれらのN− オキシド、あるいはそれらの医薬的に許容できる塩。 2.疾患状態が炎症性疾患または自己免疫疾患である、請求の範囲第1項記載の 化合物。 3.疾患状態が関節の炎症、関節炎、リューマチ様関節炎、リューマチ 様脊椎炎および変形性関節炎、敗血症、敗血症ショック、グラム陰性敗血症、毒 物ショック症候群、急性呼吸困難症候群、喘息、骨吸収疾患、レパーフュージョ ン(reperfusion)傷害、移植片対宿主反応、同種移植片拒絶マラリ ア、筋肉痛、HIV、AIDS、悪液質、クローン病(Crohn’s dis ease)、潰瘍性大腸炎、ピレシス(pyresis)、全身性円板状エリテ マトーデス、多発性硬化症、I型糖尿病、乾癬、ベケット病(Bechet’s disease)、アナフィラキシー様の紫斑病腎炎、慢性糸球体腎炎、炎症 性腸疾患、および白血病から成る群から選択される、請求の範囲第2項記載の化 合物。 4.疾患状態が関節炎である請求の範囲第3項記載の化合物。 5.請求の範囲第1項記載の化合物であって、ただしZ3が−CZNH−である ならば、 R1はハロにより置換された低級アルキルであり;または R2はハロ、シクロアルキルまたはシクロアルケニルで置換されたアルキ ル、アルケニル、ハロ、メチレン、またはアルキルで置換されたシクロアルキル 、シクロチオアルキルまたはシクロチオアルケニルであり; Z1およびZ2は酸素または硫黄であり、そして少なくとも1つのZ1およ びZ2は硫黄であり;あるいは R3はそれぞれがアラルコキシ、アルラルキルチオ、カルボキシ、アラル キルオキシカルボニル、Y1Y1N−、Y1Y2NCO−またはY1Y2NSO2−( 式中、Y1およびY2は独立して水素、アルキル、アリールであり、ただし、Y 1およびY2の1つまたは両方はアリールまたはアラルキルである)である サイクリックAMPホスホジエステラーゼの生産を阻害することによりモジュレ ートすることができる疾患状態を治療するための医薬品を製造するための化合物 。 6.疾患状態がサイクリックAMPホスホジエステラーゼの機能、好酸球蓄積ま たは好酸球の機能に関連する病理的状態である請求の範囲第5項記載の化合物。 7.病理的状態が喘息、アトピー性皮膚炎、ウリチカリア(uriticari a)、アレルギー性鼻炎、乾癬、リューマチ様関節炎、潰瘍性大腸炎、クローン 病、成人呼吸困難症候群、尿崩症、角化症、皮膚炎、大脳老化、多発性梗塞性痴 呆、老人性痴呆、パーキンソン病に合併する記憶障害、心停止、心拍動および間 欠性破行である請求の範囲第6項記載の化合物。 8.病理的状態が喘息である請求の範囲第7項記載の化合物。 9.式I 式中、 R1は低級アルキルであり; R2はアルキル、アルケニル、シクロアルキル、シクロアルケニル、シクロ チオアルキルまたはシクロチオアルケニルであり; R3はアリールまたはヘテロアリールであり; Z、Z1およびZ2は独立して酸素または硫黄であり; Z3は であり;そして Xはハロである、 のベンゼン誘導体、まはたそれらのN−オキシド、あるいはそれらの医薬的に許 容できる塩であり、ただし R1がメチルであり、R2がシクロペンチルであり、Z1およびZ2が酸素であ り、そしてR3がフェニルであるときにはZ3は−COCH2−以外であり;ある いは Z3が−CZNH−であるときには、R1はハロで置換された低級アルキルで あり;またはR2がハロ、シクロアルキルまたはシクロアルケニルで置換された アルキル、アルケニル、ハロ、メチレンまたはアルキルで置換されたシクロアル キル、シクロアルケニル、シクロチオアルキルまたはシクロチオアルケニルであ り;またはZ1およびZ2は酸素または硫黄であり、そしてすくなくとも1つのZ1 およびZ2は硫黄であり;またはR3はそれぞれアラルコキシ、アラルキルチオ 、カルボキシ、アラルキルオキシカルボニル、Y1Y2N−、Y1Y2NCO−また はY1Y2NSO2−(式中、Y1およびY2は独立して水素、アルキル、アリール またはアラルキルであり、ただしY1およびY2の1つまたは両方がアリールまた はアラルキルである)で置換されたアリールまたはヘテロアリールである、 該ベンゼン誘導体。 10.Z3が−CZNH−であり;そしてR2がハロ、シクロアルキルまたはシク ロアルケニルで置換されたアルキル、アルケニル、ハロまたはメチレンで置換さ れたシクロアルキル、シクロアルケニル、シクロチオアルキルである、請求の範 囲第9項目記載の化合物。 11.Z3が−CZNH−であり;そしてZ1およびZ2は酸素または硫黄であり 、かつすくなくとも1つのZ1およびZ2は硫黄である請求の範囲第9項目記載の 化合物。 12.Z3が−CZNH−であり;そしてR3はそれぞれアラルコキシ、アラルキ ルチオ、カルボキシ、アラルキルオキシカルボニル、Y1Y2N−、Y1Y2NCO −またはY1Y2NSO2−(式中、Y1およびY2は独立して水素、アルキル、ア リールまたはアラルキルであり、ただしY1およびY2の1つまたは両方がアリー ルまたはアラルキルである)で置換されているアリールまたはヘテロアリールで ある請求の範囲第9項目記載の化合物。 13.Z3が−CZNH2−であり、ただしR1がメチルであり、R2がシクロペ ンチルであり、Z1およびZ2が酸素であり、そしてR3がフェニルであるときは 、Zは硫黄である、請求の範囲第9項目記載の化合物。 14.Z3が である請求の範囲第9項目記載の化合物。 15.Z3が である請求の範囲第9項目記載の化合物。 16.R2がノルボニル、ノルボネニル、シクロペンチルまたはシクロペンテニ ルであるである請求の範囲第9項目記載の化合物。 17.Z1およびZ2が酸素、またはZ1が硫黄そしてZ2が酸素である請求の範囲 第9項目記載の化合物。 18.R1がハロで置換された低級アルキルである請求の範囲第9項目記載の化 合物。 19.Z3が−CZNHであり;R1がハロで置換された低級アルキルである請求 の範囲第9項目記載の化合物。 20.R1がZ1に結合しているR1の位置に隣接しているR1の位置で1つ以上の ハロで置換されている請求の範囲第9項目記載の化合物。 21.R3が2−位または2−および6−位の両方でフェニルに置換されてい請 求の範囲第9項目記載の化合物る。 22.R3がZ3に結合しているR3位に隣接している位置の1つまたは両方で置 換されているヘテロアリールである請求の範囲第9項目記載の化合物。 23.R3が3,5−ジハロピリジ−4−イルである請求の範囲第9項目記載の 化合物。 20. N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオキシ−4 −(メチルチオ)ベンズアミド; N−(3,5−ジフルオロピリジ−4−イル)−3−シクロペンチルオキシ− 4−(メチルチオ)ベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−(エキソ)−8,9,10 −トリノルボニル−2−オキシ−4−(メチルチオ)ベンズアミド; (R)−N−(3,5−ジクロロピリジ−4−イル)−3−(エキソ)−8, 9,10−トリノルボニル−2−オキシ−4−(メチルチオ)ベンズアミド; (S)−N−(3,5−ジクロロピリジ−4−イル)−3−(エキソ)−8, 9,10−トリノルボニル−2−オキシ−4−(メチルチオ)ベンズアミド; (±)−N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンタ−2 −エニルオキシ−4−メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンタ−3−エニル オキシ−4−メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオキシ−4 −ジフルオロメトキシベンズアミド; 3−シクロペンチルチオ−N−(3,5−ジクロロピリジ−4−イル)−4− メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−イソプロピルチオ−4−メ トキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオ キシ−4−(フルオロメチルチオ)−ベンズアミド; 3−シクロペンチルオキシ−4−メトキシフェニル−2’,6’−ジクロロベ ンジルケトン; 3−シクロペンチルオキシ−4−メトキシフェニル−3,5−ジクロロピリジ −4−イルメチルケトン; 3,5−ジクロロ−4−(2−(3−シクロペンチルオキシ−4−メトキシフ ェニル)−2−オキソエチル)−ピリジン−N−オキシド; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−(3−クル ロピリジ−4−イル)エタノン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−(4−ピリ ジル)エタノン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−フェニルエ タノン; 3−(3−メチル−2−ブテニルオキシ)−N−(3,5−ジクロロピリジ− 4−イル)−4−メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−[エキソビシクロ(2.2 .1)ヘプタ−5−エン−2−イルオキシ]−4−メトキシベンズアミド; N−(3−シクロペンチルオキシ−4−メトキシフェニル)−2,6−ジクロ ロベンズアミド; N−(3−シクロペンチルオキシ−4−メトキシフェニル)−2,6−ジフル オロベンズアミド; N−(2,6−ジクロロフェニル)−N’−(3−シクロペンチルオキシ−4 −メトキシフェニル)ウレア; N−(3,5−ジクロロピリジ−4−イル)−N’−(3−シクロペンチルオ キシ−4−メトキシフェニル)ウレア: 3−シクロペンチルオキシ−4−メトキシフェニル)−2,6−ジクロロベン ゾエート; 3−シクロペンチルオキシ−4−メトキシフェニル−2,6−ジクロロベンジ ルエーテル; N−(2−クロロフェニル)−3−シクロペンチルオキシ−4−メトキシベン ジルアミン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−(2,6− ジクロロフェニル)エテン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−(2,6− ジフルオロフェニル)エテン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2−(ピリジ− 4−イル)エタン−1,2−ジオン; トランス−1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2− (3,5−ジクロロピリジ−4−イル)ジアゼン; 1−(3−シクロペンチルオキシ−4−メトキシフェニル)−c−1−オキソ −r−2−(3,5−ジクロロ−1−オキソ−ピリジ−4−イル)ジアゼン; トランス−1−(3−シクロペンチルオキシ−4−メトキシフェニル)−2− (3,5−ジクロロ−1−オキソ−ピリジ−4−イル)ジアゼン; N−(2−クロロフェニル)−3−シクロペンチルオキシ−4−メトキシベン ゼンスルホンアミド; 3−シクロペンチルメトキシ−N−(3,5−ジクロロピリジ−4−イル)− 4−メトキシベンズアミド; 3−シクロプロピルメトキシ−N−(3,5−ジクロロピリジ−4−イル)− 4−メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオキシ−4 −トリフルオロエトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−(4,4−ジフルオロ−3 −メチレンシクロブタ−1−エニルオキシ)−4−メトキシベンズアミド; N−(3,5−ジフルオロピリジ−4−イル)−3−イソプロポキシ−4−ジ フルオロメトキシベンズアミド; N−(3,5−ジフルオロ−1−オキシド−4−ピリジニオ)−3−イソプロ ポキシ−4−ジフルオロメトキシベンズアミド; N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−3−イソプロポ キシ−4−ジフルオロメトキシ−ベンズアミド; N−(3,5−ジクロロ−4−ピリジル)−4−ジフルオロメトキシ−3−( エキソ)−8,9,10−トリノルボニ−2−イルオキシベンズアミド; N−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−4−ジフルオロ メトキシ−3−(エキソ)−8,9,10−トリノルボニ−2−イルオキシベン ズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−(2−フルオロシクロペン チルオキシ)−4−メトキシベンズアミド; N−(3,5−ジクロロ−ピリジ−4−イル)−3−(テトラヒドロ チオフェン−3−オキシ)−4−メトキシベンズアミド; 3−シクロペンチルオキシ−N−(3,5−ジクロロ−1−オキシド−4−ピ リジニオ)−4−ジフルオロメトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−イソプロポキシ−4−(メ チルチオ)ベンズアミド; N−(3,5−ジフルオロピリジ−4−イル)−3−イソプロポキシ−4−( メチルチオ)ベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−(ペンタ−3−イルオキシ )−4−(メチルチオ)ベンズアミド; (±)−1−[3−{(エキソ)−8,9,10−トリノルボニル−2−オキ シ}−4−メトキシフェニル]−2−(3,5−ジクロロピリジ−4−イル)エ タノン; 1−[3−シクロペンチルオキシ−4−(メチルチオ)フェニル]−2−(3 ,5−ジクロロピリジ−4−イル)エタノン; 1−(4−メトキシ−3−プロパ−2−イルオキシフェニル)−2−(3,5 −ジクロロピリジ−4−イル)エタノン; 1−(4−メチルチオ−3−プロパ−2−イルオキシフェニル)−2−(3, 5−ジクロロピリジ−4−イル)エタノン; 1−(4−メトキシ−3−プロパ−2−イルオキシフェニル)−2−(3,5 −ジクロロ−1−オキシド−4−ピリジニオ)エタノン; 1−(3−シクロペンチルオキシ−4−ジフルオロメトキシフェニル)−2− (3,5−ジクロロピリジ−4−イル)エタノン; 1−(3−シクロペンチルオキシ−4−ジフルオロメトキシフェニル)−2− (3,5−ジクロロ−1−オキシド−4−ピリジニノ)エタノン ; 2−(3,5−ジクロロピリジ−4−イル)−1−[3−{エキソビシクロ( 2.2.1)ヘプタ−5−エン−2−イルオキシ}−4−メトキシフェニル]エ タノン; 2−(3,5−ジクロロ−4−ピリジル)−1−(4−ジフルオロメトキシ− 3−(エキソ)−8,9,10−トリノルボナ−2−イルオキシフェニル)エタ ノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−[4−ジフ ルオロメトキシ−3−(エキソ)−8,9,10−トリノルボナ−2−イルオキ シフェニル)エタノン; 2−(3,5−ジクロロ−4−ピリジル)−1−[4−メトキシ−3−(3− メチル−2−ブテニルオキシ)−フェニル]エタノン; 2−(3,5−ジクロロ−4−ピリジル)−1−(4−ジフルオロメトキシ− 3−イソプロポキシフェニル)−エタノン; 2−(3,5−ジクロロ−1−オキシド−4−ピリジニオ)−1−(4−ジフ ルオロメトキシ−3−イソプロポキシフェニル)−エタノン;または 3,5−ジクロロ−4−(3−シクロペンチルオキシ−4−メトキシフェノキ シメチル)ピリジンン、である請求の範囲第9項記載の化合物。 21.N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオキシ −4−(メチルチオ)ベンズアミドである請求の範囲第20項記載の化合物。 22.N−(3,5−ジクロロピリジ−4−イル)−3−シクロペンチルオキシ −4−ジフルオロメトキシベンズアミドである請求の範囲第2 0項記載の化合物。 23.N−(3,5−ジクロロ−4−ピリジル)−4−ジフルオロメトキシ−3 −(エキソ)−8,9,10−トリノルボナ−2−イルオキシベンズアミドであ る請求の範囲第20項記載の化合物。 24.3−シクロペンチルオキシ−N−(3,5−ジフルオロピリジ−4−イル )−4−メトキシベンズアミドである請求の範囲第20項記載の化合物。 25.(3,5−ジクロロ−1−オキシド−4−ピリジニノ)−4−ジフルオロ メトキシ−3−(エキソ)−8,9,10−トリノルボナ−2−イルオキシベン ズアミドである請求の範囲第20項記載の化合物。 26.3−シクロペンチルオキシ−4−メトキシフェニル−3,5−ジクロロピ リジ−4−イルメチルケトンである請求の範囲第20項記載の化合物。 27.3,5−ジクロロ−4−(2−(3−シクロペンチルオキシ−4−メトキ シフェニル)−2−オキソエチル)−ピリジン−N−オキシドである請求の範囲 第20項記載の化合物。 28.N−(3,5−ジクロロピリジ−4−イル)−3−[エキソビシクロ(2 .2.1)ヘプタ−5−エン−2−イルオキシ]−4−メトキシベンズアミドで ある請求の範囲第20項記載の化合物。 29.2−(3,5−ジクロロピリジ−4−イル)−1−[3−{エキソビシク ロ(2.2.1)ヘプタ−5−エン−2−イルオキシ}−r−メトキシフェニル ]エタノンである請求の範囲第20項記載の化合物。 30.3−シクロペンチルオキシ−N−(3,5−ジクロロ−1−オキシド−4 −ピリジニノ)−4−ジフルオロメトキシベンズアミドである 請求の範囲第20項記載の化合物。 31.(±)−1−[3−{(エキソ)−8,9,10−トリノルボニル−2− オキシ}−4−メトキシフェニル]−2−(3,5−ジクロロピリジ−4−イル )エタノンである請求の範囲第20項記載の化合物。 32.2−(3,5−ジクロロ−4−ピリジル)−1−(4−ジフルオロメトキ シ−3−(エキソ)−8,9,10−トリノルボニ−2−イルオキシフェニル) エタノンである請求の範囲第20項記載の化合物。 33.2−(3,5−ジクロロ−1−オキシド−4−ピリジニノ)−1−[4− ジフルオロメトキシ−3−(エキソ)−8,9,10−トリノルボニ−2−イル オキシフェニル]エタノンである請求の範囲第20項記載の化合物。 34. 3−シクロペンチルオキシ−N−(3,5−ジフルオロピリジ−4−イル)−4 −メトキシベンズアミド; (R)−N−(2,6−ジクロロフェニル)−3−(エキソ−8,9,10−ト リノルボニル−2−オキシ)−4−メトキシベンズアミド; (S)−N−(2,6−ジクロロフェニル)−3−(エキソ−8,9,10−ト リノルボニル−2−オキシ)−4−メトキシベンズアミド; N−(3−ブロモ−5−クロロピリジ−4−イル)−3−シクロペンチルオキシ −4−メトキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−3−イソプロポキシ−4−メトキ シベンズアミド; 3−tert−ブトキシ−N−(3,5−ジクロロピリジ−4−イル)−4−メ トキシベンズアミド; N−(3,5−ジクロロピリジ−4−イル)−4−メトキシ−3−(ペンタ−3 −イルオキシ)ベンズアミド;または N−(3,5−ジクロロ−1−オキシド−4−ピリジニノ)−4−メトキシ−3 −(エキソ)−8,9,10−トリノルボニ−2−イルオキベンズアミドである 請求の範囲第20項記載の化合物。 35.3−シクロペンチルオキシ−N−(3,5−ジフルオロピリジ−4−イル )−4−メトキシベンズアミドである請求の範囲第21項記載の化合物。 36.N−(3,5−ジクロロ−1−オキシド−4−ピリジニノ−4−メトキシ −3−(エキソ)−8,9,10−トリノルボニ−2−イルオキシ−ベンズアミ ドである請求の範囲第21項記載の化合物。 37.請求の範囲第9項記載の化合物および医薬的に許容できるキャリアーを含 んで成る医薬組成物。 38.式VI 式中、R1、R3、Z1およびZ2は前記に定義したものであるの化合物を酸化 することを含んで成る、R1、R2、R3、Z1およびZ2が前記に定義したもので あり、Z3が−CZNH2−であり、そしてZが酸素である請求の範囲第9項の化 合物を製造する方法。 39.式VII 式中、R1、R2、Z、Z1およびZ2は前記に定義したものであり、 そしてR4およびR5は低級アルキルを表す の化合物を、式VIII R3CH3 VIII 式中、R3は前記に定義したものである の化合物と、カップリングさせることを含んで成る、R1、R2、R3、Z1および Z2が前記に定義したものであり、Z3が−CZCH2−であり、そしてZが酸素 である請求の範囲第9項記載の化合物の製造法。 40.式IX 式中、R1、R2、Z1およびZ2は前記に定義したものである、 の化合物を、式X R3MgX X 式中、R3およびXは前記に定義したものである、 の化合物と反応させることを含んで成るR1、R2、R3、Z1およびZ2 が前記に定義したものであり、Z3が−CZCH2−であり、そしてZが酸素であ る請求の範囲第9項記載の化合物の製造法。 41.実質的に前記に記載された請求の範囲第9項記載の化合物の製造法。 42.請求の範囲第1項記載の化合物のTNFの抑制に効果的な量を含んで成る 、病理的に有害なTNF量に随伴する疾患状態の治療に有用な医薬組成物。 43.Z3が−CZNHであるときは R1はハロで置換された低級アルキルであり;または R2はハロ、シクロアルキルまたはシクロアルケニルで置換されたアルキル 、アルケニル、ハロ、メチレンまたはアルキルで置換されたシクロアルキル、シ クロアルケニル、シクロチオアルキルまたはシクロチオアルケニルであり;また は Z1およびZ2は酸素または硫黄であり、そしてすくなくとも1つのZ1およ びZ2は硫黄であり; またはR3はそれぞれアラルコキシ、アラルキルチオ、カルボキシ、アラル キルオキシカルボニル、Y1Y2N−、Y1Y2NCO−またはY1Y2NSO2−( 式中、Y1およびY2は独立して水素、アルキル、アリールまたはアラルキルであ り、ただしY1およびY2の1つまたは両方がアリールまたはアラルキルである) である置換されたアリールまたはヘテロアリールである 請求の範囲第1項記載の化合物のサイクリックAMPホスホジエステラーゼの阻 害に効果的な量を含んで成る、病理的に有害なサイクリックAMPホスホジエス テラーゼ量に随伴する疾患状態の治療に有用な医薬組 成物。 43.式I 式中、 R1は低級アルキルであり; R2はアルキル、アルケニル、シクロアルキル、シクロアルケニル、シクロ チオアルキルまたはシクロチオアルケニルであり; R3はアリールまたはヘテロアリールであり; Z、Z1およびZ2は独立して酸素または硫黄であり; Z3は であり;そして Xはハロである、 の化合物のベンゼン誘導体、またはそれらのN−オキシド、あるいはそれらの医 薬的に許容できる塩の有効量を、TNFを抑制することによりモジュレートする ことができる疾患状態の患者に投与することを含んで成る、該疾患状態の治療法 。 44.疾患状態が炎症性疾患または自己免疫疾患である、請求の範囲第43項記 載の化合物。 45.疾患状態が関節の炎症、関節炎、リューマチ様関節炎、リューマチ様脊椎 炎および変形性関節炎、敗血症、敗血症ショック、グラム陰性敗血症、毒物ショ ック症候群、急性呼吸困難症候群、喘息、骨吸収疾患、レパーフュージョン(r eperfusion)傷害、移植片 対 宿主反応、同種移植片拒絶マラリア 、筋肉痛、HIV、AIDS、悪液質、クローン病(Crohn’s dise ase)、潰瘍性大腸炎、ピレシス(pyresis)、全身性円板状エリテマ トーデス、多発性硬化症、I型糖尿病、乾癬、ベケット病(Bechet’s disease)、アナフィラキシー様の紫斑病腎炎、慢性糸球体腎炎、炎症性 腸疾患、および白血病から成る群から選択される、請求の範囲第44項記載の治 療法。 46.疾患状態が関節炎である請求の範囲第45項記載の治療法。 47.Z3が−CZNH−であるならば、 R1はハロにより置換された低級アルキルであり;または R2はハロ、シクロアルキルまたはシクロアルケニルで置換されたアルキ ル、アルケニル、ハロ、メチレン、またはアルキルで置換されたシクロアルキル 、シクロチオアルキルまたはシクロチオアルケニルであり; Z1およびZ2は酸素または硫黄であり、そして少なくとも1つのZ1およ びZ2は硫黄であり;あるいは R3はアルキルチオ、カルボキシまたはアラルキルオキシカルボニルによ り置換されたアリール、またはアラルキルチオカルボキ シまたはアラルキルオキシカルボニルにより置換されたヘテロアリールである 請求の範囲第1項記載の化合物の有効量を、サイクリックAMPホスホジエステ ラーゼの生産を阻害することによりモジュレートすることができる疾患状態にか かっている患者に投与することを含んで成る、該疾患状態の治療法。 48.疾患状態がサイクリックAMPホスホジエステラーゼの機能、好酸球蓄積 または好酸球の機能に関連する病理的状態である請求の範囲第47項記載の治療 方法。 49.病理的状態が喘息、アトピー性皮膚炎、ウリチカリア(uriticar ia)、アレルギー性鼻炎、乾癬、リューマチ様関節炎、潰瘍性大腸炎、クロー ン病、成人呼吸困難症候群、尿崩症、角化症、皮膚炎、大脳老化、多発性梗塞性 痴呆、老人性痴呆、パーキンソン病に合併する記憶障害、心停止、心拍動および 間欠性跛行である請求の範囲第48項記載の方法。 50.病理的状態が喘息である請求の範囲第49項記載の方法。
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929215989A GB9215989D0 (en) | 1992-07-28 | 1992-07-28 | Novel compounds |
GB9216005.0 | 1992-07-28 | ||
GB929216005A GB9216005D0 (en) | 1992-07-28 | 1992-07-28 | New compounds |
GB929216008A GB9216008D0 (en) | 1992-07-28 | 1992-07-28 | Novel compositions of matter |
GB9216006.8 | 1992-07-28 | ||
GB929216006A GB9216006D0 (en) | 1992-07-28 | 1992-07-28 | New use |
GB9215989.6 | 1992-07-28 | ||
GB9216008.4 | 1992-07-28 | ||
GB929216764A GB9216764D0 (en) | 1992-08-07 | 1992-08-07 | Novel compounds |
GB9216764.2 | 1992-08-07 | ||
GB939310633A GB9310633D0 (en) | 1993-05-21 | 1993-05-21 | New compositions of matter |
GB9310633.4 | 1993-05-21 | ||
GB939310938A GB9310938D0 (en) | 1993-05-27 | 1993-05-27 | New compositions of matter |
GB9310938.7 | 1993-05-27 | ||
GB939311281A GB9311281D0 (en) | 1993-06-01 | 1993-06-01 | Novel composition of matter |
GB9311281.1 | 1993-06-01 | ||
GB939314847A GB9314847D0 (en) | 1993-07-16 | 1993-07-16 | New use |
GB9314847.6 | 1993-07-16 | ||
PCT/GB1993/001597 WO1994002465A1 (en) | 1992-07-28 | 1993-07-28 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08503925A true JPH08503925A (ja) | 1996-04-30 |
JP3775684B2 JP3775684B2 (ja) | 2006-05-17 |
Family
ID=27576348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50433094A Expired - Lifetime JP3775684B2 (ja) | 1992-07-28 | 1993-07-28 | 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0652868B1 (ja) |
JP (1) | JP3775684B2 (ja) |
AT (1) | ATE282025T1 (ja) |
AU (1) | AU4717693A (ja) |
CA (1) | CA2140441C (ja) |
CZ (1) | CZ14795A3 (ja) |
DE (1) | DE69333688T2 (ja) |
DK (1) | DK0652868T3 (ja) |
ES (1) | ES2227519T3 (ja) |
FI (1) | FI950375A0 (ja) |
HU (1) | HUT72656A (ja) |
IL (1) | IL106517A0 (ja) |
MX (1) | MX9304571A (ja) |
NO (1) | NO950319L (ja) |
NZ (1) | NZ254881A (ja) |
PL (1) | PL307265A1 (ja) |
PT (1) | PT652868E (ja) |
WO (1) | WO1994002465A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001509158A (ja) * | 1997-01-22 | 2001-07-10 | ローン−プーラン・ロレ・フアーマシユーチカルズ・インコーポレーテツド | 置換β−チオカルボン酸類 |
JP2013151522A (ja) * | 2005-07-26 | 2013-08-08 | Novipharma Sa | Comt阻害剤 |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9212673D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
GB9222253D0 (en) * | 1992-10-23 | 1992-12-09 | Celltech Ltd | Chemical compounds |
GB9226830D0 (en) * | 1992-12-23 | 1993-02-17 | Celltech Ltd | Chemical compounds |
US5622977A (en) * | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
GB9304920D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
GB9304919D0 (en) * | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5712298A (en) * | 1993-07-02 | 1998-01-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
ATE218549T1 (de) | 1993-07-28 | 2002-06-15 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
GB9326173D0 (en) * | 1993-12-22 | 1994-02-23 | Celltech Ltd | Chemical compounds and process |
JP3806144B2 (ja) * | 1993-12-22 | 2006-08-09 | セルテック セラピューティックス リミテッド | 三置換フェニル誘導体、その調製方法とホスホジエステラーゼ(iv型)阻害剤としてのその使用 |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
US6245774B1 (en) | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
US5786354A (en) * | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412573D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412571D0 (en) | 1994-06-22 | 1994-08-10 | Celltech Ltd | Chemical compounds |
GB9412672D0 (en) * | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
US5591776A (en) * | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
JPH10508032A (ja) * | 1994-12-13 | 1998-08-04 | ユーロ−セルティーク,エス.エイ. | アリールチオキサンチン類 |
TW375612B (en) * | 1995-04-06 | 1999-12-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same |
GB9507297D0 (en) * | 1995-04-07 | 1995-05-31 | Rh Ne Poulenc Rorer Limited | New composition of matter |
EP0828728B1 (de) * | 1995-05-18 | 2003-01-22 | ALTANA Pharma AG | Phenyldihydrobenzofurane |
JPH11505539A (ja) * | 1995-05-18 | 1999-05-21 | ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルジヒドロベンゾフラン |
AU5772196A (en) * | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
WO1996036596A1 (en) * | 1995-05-19 | 1996-11-21 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
AU5772296A (en) * | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
US6268373B1 (en) | 1995-06-07 | 2001-07-31 | Euro-Celtique S.A. | Trisubstituted thioxanthines |
AU6526896A (en) * | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
ATE197038T1 (de) | 1995-07-26 | 2000-11-15 | Pfizer | N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526245D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9526246D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
US6294541B1 (en) | 1996-06-06 | 2001-09-25 | Euro-Celtique S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
AU3102697A (en) | 1996-06-19 | 1998-01-07 | Rhone-Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
US5744473A (en) * | 1996-09-16 | 1998-04-28 | Euro-Celtique, S.A. | PDE IV inhibitors: "bis-compounds" |
EP0934280B1 (en) * | 1996-10-02 | 2003-04-09 | Janssen Pharmaceutica N.V. | Pde iv inhibiting 2-cyanoiminoimidazole derivatives |
GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
GB9625184D0 (en) * | 1996-12-04 | 1997-01-22 | Celltech Therapeutics Ltd | Chemical compounds |
US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
GB9713087D0 (en) * | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
NZ502965A (en) * | 1997-11-25 | 2002-03-01 | Warner Lambert Co | Benzenesulfonamide inhibitors of phosphodiesterase-IV for treating inflammation and TNF associated diseases |
CN1294590A (zh) | 1997-12-12 | 2001-05-09 | 欧罗赛铁克股份有限公司 | 通过2-硫代黄嘌呤制备3-取代腺嘌呤的方法 |
PT1086096E (pt) | 1998-06-10 | 2003-12-31 | Altana Pharma Ag | Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4 |
US6319928B1 (en) | 1998-11-30 | 2001-11-20 | Euro-Celtique, S.A. | Purine derivatives having phosphodiesterase IV inhibition activity |
PT1161239E (pt) * | 1999-03-10 | 2005-02-28 | Altana Pharma Ag | 3-ciclopropilmetoxi-4-difluorometoxi-n-(3,5-dicloropirid-4-il)-benzamida para o tratamento da esclerose multipla |
CN1377353A (zh) | 1999-04-02 | 2002-10-30 | 欧罗赛铁克股份有限公司 | 具有磷酸二酯酶iv抑制活性的嘌呤衍生物 |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
IL147688A0 (en) | 1999-08-21 | 2002-08-14 | Byk Gulden Lomberg Chem Fab | Synergistic combination |
GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
AU6196201A (en) * | 2000-05-25 | 2001-12-03 | Merck Frosst Canada Inc | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
US20020183393A1 (en) * | 2000-09-15 | 2002-12-05 | Morgans David J. | Inhibitors of Rho C |
TWI262920B (en) | 2000-10-27 | 2006-10-01 | Elbion Ag | New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them |
US6699890B2 (en) | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US7153871B2 (en) | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
JP4510383B2 (ja) * | 2001-05-23 | 2010-07-21 | 田辺三菱製薬株式会社 | 軟骨疾患修復治療用組成物 |
KR20040007596A (ko) * | 2001-05-23 | 2004-01-24 | 다나베 세이야꾸 가부시키가이샤 | 골절 치료 촉진용 조성물 |
RS94703A (en) | 2001-05-29 | 2007-02-05 | Schering Aktiengesellschaft, | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
EP1539697A1 (en) | 2002-07-19 | 2005-06-15 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
AU2003256601B2 (en) | 2002-07-19 | 2009-10-29 | Memory Pharmaceuticals Corporation | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
CN100532374C (zh) | 2002-10-23 | 2009-08-26 | 格兰马克药品有限公司 | 可用于治疗炎性和变应性病症的新的三环化合物:它们的制备方法以及包含它们的药物组合物 |
US7087625B2 (en) | 2002-11-19 | 2006-08-08 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
BRPI0406427B8 (pt) | 2003-03-10 | 2021-05-25 | Astrazeneca Ab | processo para a preparação de roflumilast |
KR20050115331A (ko) | 2003-04-01 | 2005-12-07 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | 불임증 포스포디에스터라제의 억제제 |
AU2004228453B2 (en) | 2003-04-11 | 2010-08-19 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
US7776893B2 (en) | 2003-09-05 | 2010-08-17 | Nycomed Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
EP1799632A2 (en) | 2004-10-13 | 2007-06-27 | Glenmark Pharmaceuticals S.A. | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methanesulfonamido-dibenzo[b,d]furan-1-carboxamide |
EP1831227B1 (en) | 2004-12-17 | 2013-06-19 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
US7943634B2 (en) | 2004-12-17 | 2011-05-17 | Glenmark Pharmaceuticals S.A. | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors |
BRPI0609371A2 (pt) | 2005-03-08 | 2010-03-30 | Nycomed Gmbh | usos de roflumilast na produção de composições farmacêuticas para o tratamento de diabetes mellitus |
WO2008006509A1 (en) * | 2006-07-14 | 2008-01-17 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
EP1886990A1 (en) * | 2006-08-01 | 2008-02-13 | Neuropharma S.A. | Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders |
ES2374337T3 (es) | 2007-05-16 | 2012-02-15 | Nycomed Gmbh | Derivados de pirazolona como inhibidores de pde4. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
DE102007026875A1 (de) * | 2007-06-11 | 2008-12-24 | Bayer Cropscience Ag | 3-Cyclopropyl-4-(3-thiobenzoyl)pyrazole und ihre Verwendung als Herbizide |
EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
EP2070913A1 (en) | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
FR2962649A1 (fr) | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EA201391254A1 (ru) | 2011-03-01 | 2014-02-28 | Синерджи Фармасьютикалз Инк. | Способ получения агонистов гуанилатциклазы c |
KR20140028049A (ko) | 2011-06-06 | 2014-03-07 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제인 1-페닐-2-피리디닐 알킬 알콜의 유도체 |
CN103827088B (zh) | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
CN103889972A (zh) | 2011-10-21 | 2014-06-25 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
WO2013131255A1 (en) | 2012-03-07 | 2013-09-12 | Scinopharm (Changshu) Pharmaceutical, Ltd. | Preparation method of roflumilast |
CN104334542A (zh) | 2012-06-04 | 2015-02-04 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物 |
ES2716142T3 (es) | 2012-12-05 | 2019-06-10 | Chiesi Farm Spa | Derivados del alcohol de 1-fenil-2-piridinil alquilo como inhibidores de la fosfodiesterasa |
CA2902348C (en) | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
US20160184387A1 (en) | 2013-08-09 | 2016-06-30 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
JP2017222576A (ja) * | 2014-10-31 | 2017-12-21 | 石原産業株式会社 | 有害生物防除剤 |
CN109134358B (zh) * | 2018-09-20 | 2020-08-04 | 浙江理工大学 | 一种3,5-二溴-4-氨基吡啶的合成方法 |
CN114340631A (zh) | 2019-05-21 | 2022-04-12 | 阿德利克斯股份有限公司 | 用于降低患者的血清磷酸盐的组合 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9007762D0 (en) * | 1990-04-05 | 1990-06-06 | Beecham Group Plc | Novel compounds |
BR9106653A (pt) * | 1990-07-10 | 1993-06-08 | Smithkline Beecham Corp | Oxamidas |
US5124455A (en) * | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
KR930703262A (ko) * | 1990-11-06 | 1993-11-29 | 스튜어트 알. 슈터 | 이미다졸리디논 화합물 |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
-
1993
- 1993-07-28 EP EP93917937A patent/EP0652868B1/en not_active Expired - Lifetime
- 1993-07-28 CA CA002140441A patent/CA2140441C/en not_active Expired - Lifetime
- 1993-07-28 IL IL10651793A patent/IL106517A0/xx unknown
- 1993-07-28 MX MX9304571A patent/MX9304571A/es unknown
- 1993-07-28 NZ NZ254881A patent/NZ254881A/en unknown
- 1993-07-28 AU AU47176/93A patent/AU4717693A/en not_active Abandoned
- 1993-07-28 WO PCT/GB1993/001597 patent/WO1994002465A1/en active IP Right Grant
- 1993-07-28 CZ CZ95147A patent/CZ14795A3/cs unknown
- 1993-07-28 JP JP50433094A patent/JP3775684B2/ja not_active Expired - Lifetime
- 1993-07-28 HU HU9500265A patent/HUT72656A/hu unknown
- 1993-07-28 AT AT93917937T patent/ATE282025T1/de active
- 1993-07-28 PL PL93307265A patent/PL307265A1/xx unknown
- 1993-07-28 ES ES93917937T patent/ES2227519T3/es not_active Expired - Lifetime
- 1993-07-28 DK DK93917937T patent/DK0652868T3/da active
- 1993-07-28 PT PT93917937T patent/PT652868E/pt unknown
- 1993-07-28 DE DE69333688T patent/DE69333688T2/de not_active Expired - Lifetime
-
1995
- 1995-01-27 FI FI950375A patent/FI950375A0/fi unknown
- 1995-01-27 NO NO950319A patent/NO950319L/no unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001509158A (ja) * | 1997-01-22 | 2001-07-10 | ローン−プーラン・ロレ・フアーマシユーチカルズ・インコーポレーテツド | 置換β−チオカルボン酸類 |
JP2013151522A (ja) * | 2005-07-26 | 2013-08-08 | Novipharma Sa | Comt阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0652868A1 (en) | 1995-05-17 |
PL307265A1 (en) | 1995-05-15 |
DE69333688D1 (de) | 2004-12-16 |
ES2227519T3 (es) | 2005-04-01 |
NZ254881A (en) | 1996-09-25 |
CA2140441A1 (en) | 1994-02-03 |
DE69333688T2 (de) | 2005-11-03 |
EP0652868B1 (en) | 2004-11-10 |
FI950375A (fi) | 1995-01-27 |
ATE282025T1 (de) | 2004-11-15 |
WO1994002465A1 (en) | 1994-02-03 |
HU9500265D0 (en) | 1995-03-28 |
MX9304571A (es) | 1994-05-31 |
HUT72656A (en) | 1996-05-28 |
DK0652868T3 (da) | 2005-02-14 |
FI950375A0 (fi) | 1995-01-27 |
NO950319L (no) | 1995-03-27 |
CZ14795A3 (en) | 1996-07-17 |
IL106517A0 (en) | 1994-08-26 |
NO950319D0 (no) | 1995-01-27 |
JP3775684B2 (ja) | 2006-05-17 |
AU4717693A (en) | 1994-02-14 |
CA2140441C (en) | 2006-11-21 |
PT652868E (pt) | 2005-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08503925A (ja) | 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物 | |
JP3953096B2 (ja) | サイクリックampホスホジエステラーゼおよびtnf阻害剤としての置換芳香族化合物 | |
US6255326B1 (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group | |
US5935978A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | |
US5679696A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group | |
JP3775685B2 (ja) | Pde▲iv▼およびtnf抑制剤としての化合物 | |
JP4748338B2 (ja) | ベンゼン誘導体及びその医薬用途 | |
PL211388B1 (pl) | Związek amidowy, kompozycja farmaceutyczna zawierająca ten związek, zastosowanie związku do leczenia chorób, w których korzystne jest hamowanie dehydrogenazy dihydroorotanowej, sposób wytwarzania tego związku oraz zastosowanie aminy i bezwodnika kwasowego w tym sposobie | |
LV12258B (en) | DIAMINOCYCLOBUTE-3,4-DIONES AS GLUDO MUSCULAR RELAXATION | |
JP2009516746A (ja) | 化合物 | |
JP2009516694A (ja) | 化合物 | |
JP2005506983A (ja) | 炎症の治療のための置換ピラゾリル化合物 | |
US5840724A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or | |
US6096768A (en) | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | |
WO1999027965A1 (fr) | Agents anti-hyperlipemiques | |
US20080070951A1 (en) | Non-Nucleotide Reverse Transcriptase Inhibitors | |
JPH11507331A (ja) | 4,4−(二置換)シクロヘキサン−1−オール類モノマーおよび関連化合物 | |
HU211979A9 (hu) | Arii- vagy heteroaril-csoporthoz egy alifás, vagy heteroatomot tartalmazó, összekötő csoporton át kapcsolódó, fenilcsoportot tartalmazó vegyületek | |
JPS63185923A (ja) | 抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040705 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050930 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060217 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090303 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100303 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110303 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120303 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130303 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130303 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140303 Year of fee payment: 8 |
|
EXPY | Cancellation because of completion of term |